CDKN1B and neoplasm: Furthermore, miR-221 can facilitate cell cycle progression and proliferation via down-regulation of the tumor-suppressor p27Kip1/CDKN1B and the receptor tyrosine kinase c-KIT, thereby promoting melanoma progression both in vitro and in vivo [194,195].